Abstracts tagged "co-stimulation and rheumatoid arthritis (RA)"

Abstract Number: L07 • 2018 ACR/ARHP Annual Meeting
VIB4920, a Novel, Engineered CD40L Antagonist Decreased Disease Activity and Improved Biomarkers of Immune Activation in Patients with Active Rheumatoid Arthritis in a Phase 1b, Multiple-Ascending Dose Proof-of-Concept Study
Marius Albulescu¹, Ulf Müller-Ladner², Rachel Moate³, Kate Middleton³, Liangwei Wang⁴, Jorn Drappa⁴ and Gabor Illei⁵, ¹Clinical Development, MedImmune, Cambridge, UK, Cambridge, United Kingdom, ²Dept. of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus-Liebig-University Giessen, Germany, Bad Nauheim, Germany, ³MedImmune, Cambridge, UK, Cambridge, United Kingdom, ⁴Viela Bio, Gaithersburg, USA, Gaithersburg, MD, ⁵Viela Bio, Gaithersburg, USA, Gaithersberg, MD
Background/Purpose: The CD40L/CD40 co-stimulatory pathway is important for T-cell-dependent antibody production and plays a central role in RA and other autoimmune diseases. VIB4920 (formerly MEDI4920)…
Abstract Number: 1328 • 2017 ACR/ARHP Annual Meeting
A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgDTM) Potently Suppresses Mouse Collagen-Induced Arthritis and Human Xenograft Graft Vs. Host Disease (GvHD)
Stacey Dillon¹, Katherine Lewis¹, Ryan Swanson², Lawrence Evans², Michael Kornacker³, Steve Levin², Martin Wolfson⁴, Erika Rickel², Susan Bort², Sherri Mudri¹, Aaron Moss¹, Michelle Seaberg¹, Janhavi Bhandari⁴, Sean MacNeil⁴, Joe Hoover⁴, Mark Rixon⁴ and Stanford Peng⁵, ¹Translational Sciences, Alpine Immune Sciences, Seattle, WA, ²Immunology, Alpine Immune Sciences, Seattle, WA, ³Protein Engineering, Alpine Immune Sciences, Seattle, WA, ⁴Protein Therapeutics, Alpine Immune Sciences, Seattle, WA, ⁵Clinical, R&D, Alpine Immune Sciences, Seattle, WA
Background/Purpose: Our proprietary variant Ig domain (vIgD) platform creates novel, therapeutically-applicable protein domains with tailored specificity and affinity. These vIgDs are created through directed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].